DPDharma Ram Poonia

Dharma Ram Poonia

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dharma Ram Poonia has a total of 168 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Sentinel Lymph Node Biopsy in Post‐Neoadjuvant Chemotherapy Breast Cancer Patients Using a Combination of Fluorescein and Blue Dye Versus Blue Dye Alone: Randomized Pilot Feasibility Trial

    by Byshetty Rajendar, Jeewan Ram Vishnoi, Nivedita Sharma, Dharma Ram Poonia, Rahul Yadav, Taruna Yadav, Poonam Elhence, Puneet Pareek, Sanjeev Misra

    Background: Sentinel lymph node biopsy is standard for staging clinically node‐negative (cN0) breast cancer, but the dual tracer gold‐standard radioisotope–blue dye technique is unavailable in resource‐limited settings. Fluorescein, an inexpensive, safe, visible‐light tracer, has no randomized data after neoadjuvant chemotherapy (NACT). We compared fluorescein–methylene blue with methylene blue alone for sentinel lymph node biopsy in post‐NACT cN0 patients and, secondarily, assessed the accuracy of axillary ultrasound. Methods: In this randomized pilot feasibility trial, post‐NACT cN0 breast cancer patients were randomized 1:1 to fluorescein–methylene blue (FlaB) or methylene blue alone after dye allergy testing. All patients underwent completion axillary lymph node dissection as the reference standard. Identification rate and false‐negative rate were estimated with 95% confidence intervals. Results: Of 136 patients who received NACT, 62 (45.6%) had a clinical complete nodal response and were recruited; 2 (3.2%) were excluded for methylene blue allergy, leaving 30 randomized per group, with all 60 completing the protocol. IR: 93.3% (28/30; 95% CI, 78.7–98.1) with FlaB versus 83.3% (25/30; 95% CI, 66.4–92.7) with methylene blue alone (difference, 10.0 percentage points; p = 0.23). FNR: 11.1% (2/18; 95% CI, 3.1–32.8) versus 12.5% (2/16; 95% CI, 3.5–36.0; p = 0.87). On secondary analysis, axillary ultrasound was normal in 30 of 62 patients (48.4%) and suspicious in 32 (51.6%); against final pathology, its sensitivity was 80.6%, and its negative predictive value was 76.7%; 7 of the 36 node‐positive patients (19.4%) had a sonographically normal axilla. No dye‐related adverse events occurred. Conclusion: FlaB achieved an identification rate above the 90% benchmark and a false‐negative rate comparable to radioisotope‐based dual‐tracer series. Axillary ultrasound did not reliably exclude residual nodal disease (negative predictive value 76.7%) and cannot replace pathological nodal staging after NACT. Fluorescein–methylene blue is a safe, radioisotope‐free dual‐tracer strategy for SLNB in resource‐limited settings.

  • Early Prediction of Pathological Response to Neoadjuvant Chemotherapy using Interim 18 F-FDG PET/CT in Stage II-III Breast Cancer: A Prospective Cohort Study

    by Arvind Kumar Koslia, Jeewan Ram Vishnoi, Dharma Ram Poonia, Nivedita Sharma, Ananth S. Mathad, Puneet Pareek, Parmod Kumar, Rajesh Kumar, Poonam Elhence

  • Primary tongue leiomyosarcoma

    by Atul Kumar Gupta, Bharti Devnani, Dharma Ram Poonia, Rashim Sharma, Deepak Vedant

    Leiomyosarcomas (LMS) are malignant tumours of smooth muscle origin, accounting for about 7% of all soft tissue sarcomas. Head and neck LMS constitute less than 3% of all LMS. Intra-oral LMS are rare, making up only 0.01%–0.04% of all malignancies in the oral cavity. Tongue involvement is even rarer with very few case reports available. The present case is of a male patient in his mid 50s with a 1-year history of a non-healing ulcer over the right lateral border of the tongue with impaired tongue movement who was diagnosed with LMS of the tongue on histopathological examination. He was treated with surgical excision followed by radiotherapy and chemotherapy in view of advanced stage and high-grade features. At the 8-month follow-up, the patient remains disease free without evidence of recurrence or metastasis. This case highlights the importance of multi-disciplinary management of this entity with judicial use of systemic as well as local treatment modalities.

  • Open Access

    Redefining cardiac risk in breast radiotherapy: a substructure-based dosimetric and biomarker correlation study

    by Rishi P. Nair, Depanshu Aggarwal, Atul Gupta, Bharti Devnani, Puneet Pareek, Akanksha Solanki, Parmod Kumar, Jeewan Ram Bishnoi, Dharma Ram Poonia, Nivedita Sharma

    This study aimed to evaluate the efficacy of the mean heart dose (MHD) as a predictor of radiation exposure to cardiac substructures and its association wi


  • Preserving a Functional Foot: Limb-Salvage Surgery with Brachy Mono-Therapy for Soft Tissue Sarcoma

    by Atul Anand, Dharma Ram Poonia, Nivedita Sharma, Jeewan Ram Vishnoi, Bharti Devnani, Deepti Katrolia

    Soft tissue sarcomas (STS) of the foot are rare, accounting for 2–5% of musculoskeletal sarcomas, and are often associated with higher amputation rates due to limited soft tissue coverage, complex anatomy, and the functional demands of weight-bearing. We report the case of a 70-year-old woman with a myxoinflammatory fibroblastic sarcoma involving the 2nd–4th metatarsals. Limb salvage surgery was performed, consisting of en bloc resection with preservation of the metatarso-phalangeal joints, skeletal fixation with titanium plates, tendon reconstruction using tensor fascia lata, and soft-tissue coverage with an anterolateral thigh free flap. Intraoperative, interstitial brachytherapy catheters were placed, enabling 36 Gy/9 fractions safely without wound or flap complications. At 6 months, the patient was disease-free and ambulatory without disability. This case demonstrates that with multidisciplinary planning, complex reconstruction and adjuvant brachytherapy can achieve durable local control and preserve function in selected patients with foot sarcoma.

  • Open Access

    Upfront surgery versus induction chemotherapy followed by surgery in oral cavity squamous cell cancers with advanced nodal disease (SurVIC Trial): a phase 3 multicentre randomised controlled trial

    by Dharma Ram Poonia, Amit Sehrawat, Jeewan Ram Vishnoi, Nivedita Sharma, Parmod Kumar, Bharti Devnani, Aparna Warriere, Akanksha Solanki, Puneet Pareek, Divya Aggarwal, et al.

    Introduction Most oral cancers in India present in advanced stages and tend to have poor oncological outcomes. Chemotherapy has been associated with improved oncological outcomes in various cancers, but its role in oral cancer is still not well-defined in curative settings beyond radiosensitisation. Despite an excellent response rate, neoadjuvant chemotherapy trials have failed to show an oncological advantage. Earlier studies were limited by their heterogeneous patient population, including all head and neck subsites, and included both inoperable cancer and early-stage operable cases. Due to such patient selection, the intended results were never met. Patients with biologically aggressive diseases (advanced nodal disease) may derive greater benefit from induction chemotherapy (ICT). Therefore, we aim to determine the oncological advantage of adding ICT to oral squamous cell cancer with advanced nodal disease (N2–N3). Methods and analysis The study is an open-label, multicentre, randomised controlled trial, with an allocation ratio of 1:1, being conducted at seven leading cancer centres in India. The primary objective is to compare survival outcomes with and without ICT before surgery in patients with oral squamous cell carcinoma (OSCC) and advanced nodal disease, specifically focusing on 2-year disease-free survival (DFS). Secondary objectives include assessing overall survival (OS), clinical and pathological response rates, treatment compliance, treatment completion rates, adverse events, treatment-related toxicity (using Common Terminology Criteria for Adverse Events, V.5.0), quality of life (measured with Functional Assessment of Cancer Therapy-General and Functional Assessment of Cancer Therapy-Head and Neck) and postoperative complications (using the modified Clavien-Dindo classification). The study population consists of patients with operable OSCC and advanced nodal disease (N2–N3), adequate organ function, aged 18–65 years and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0–2. The treatment arms are the standard arm Surgery arm (SURG), which involves surgery followed by adjuvant radiotherapy with or without concurrent chemotherapy, and the experimental arm (ICT), in which patients will receive two cycles of ICT using either cisplatin, docetaxel and 5-fluorouracil or cisplatin, docetaxel and capecitabine, followed by surgery and adjuvant radiotherapy with or without concurrent chemotherapy. The sample size was calculated to detect an HR of 0.67 with 80% power. A total of 184 events are required, and with an accrual rate of 15 patients per month, 300 patients will be recruited. DFS analysis will occur 32 months after the trial begins, and follow-up will continue for 5 years. OS analysis will be conducted when 184 deaths are observed. Taking 10% of the withdrawal of consent, a total of 346 patients need to be included. Ethics and dissemination This trial aims to establish the potential superiority of ICT or definitively determine its futility in OSCC with advanced nodal disease. A positive outcome could provide practice-changing data, particularly for Indian patients, whereas negative results could halt the use of ICT in this setting, directing research efforts towards more effective treatment strategies. Trial registration number CTRI/2024/03/064586; NCT06737822; Institutional Ethics Committee (IEC) number: AIIMS/IEC/2023/4622 (lead site).


  • Snowflake Model: Redefining and Optimizing the Cancer Care Delivery System in Tier 2 and Tier 3 Cities in India

    by Shashank Bansal, Ankit Jain, Vikas Jagtap, Jeewan Ram Vishnoi, Saikat Das, Rubu Sunku, Satya Sadhan Sarangi, Dharma Ram Poonia, Ketan Mehra, Rakesh Mishra